About
Who we are
We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47.
Our Technology
Experienced leadership
Management

Jacek Antas
CEO

Hatem Kawar
CFO

Namrata Malhotra
Corporate Secretary

Christof Bohler
Advisor to the BoD

Atul Deshpande
Advisor to the BoD

Frank Gary Renshaw
Board of directors

Jacek Antas
CEO and Director

Jerzy Leszczyński
Board Member and Audit Comm Chair

Christopher Maceijewski
Board Member

Malgorzata Laube
Director
Scientific and Strategic Advisory Board(SSAB)

Robert Gillies
Dr. Robert Gillies holds the Martin Silbiger Endowed Chair and is Chair of the Department of Cancer Physiology and Vice-Chair (Research) of the Department of Radiology, H. Lee Moffitt Cancer Center and Research Institute; and Professor Emeritus, Departments of Radiology and Biomedical Engineering, College of Medicine University of Arizona. He is past president of the Society for Molecular Imaging and has served on numerous grant review panels for the NIH and the DoD, consulting on cancer physiology and imaging. Dr. Gillies is an expert in tumor acidity and has published extensively in this area of research.

Frank Gary Renshaw
Dr. Renshaw is the Chief Medical Officer of Zhejiang DTRM Biopharma Co. Ltd. Previous roles included Medical Oncology Director at Eisai; Global Executive Director Level II, Oncology and Hematology R&D at Celgene Corporate; Executive Director at Celsion Corporation and Global Clinical Lead; and Clinical Pharm Lead at Bayer Health Care Corporation. Dr. Renshaw participates in a number of oncology industry committees and task forces